Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

NCT01146990 is registered in ClinicalTrials.gov with AMAG Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01146990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01146990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth
Lead sponsor
AMAG Pharmaceuticals, Inc.
Phase
Observational
Overall status
Completed
Start date
November 9, 2010
Completion date
August 13, 2020
Enrollment
245 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

children whose mothers received 17p and those who received vehicle in the 17p efficacy trial